文献速递慢性肾脏病

SGLT2抑制剂:未来哪些慢性肾脏病患者应接受治疗?

Sodium-glucose cotransporter 2 inhibition: which patient with chronic kidney disease should be treated in the future?
PubMed 文献 · Nephrol Dial Transplant · 2020-01-01

综述还评估了可能影响CKD患者使用SGLT2抑制剂的关键患者特征和合并用药,讨论了当前指南推荐,并探索了未来这些药物在CKD患者中的使用方式,包括与其他治疗联合。

要点

  • CREDENCE试验显示卡格列净可预防2型糖尿病合并CKD患者的肾衰竭和心血管事件。
  • SGLT2抑制剂的获益是在当前标准治疗基础上额外获得的。

核心结论

  • SGLT2抑制剂是2型糖尿病合并CKD患者治疗的重要进展,卡格列净已证实可预防肾衰竭和心血管事件。

研究设计与样本

  • 本文为综述,总结SGLT2抑制剂在2型糖尿病合并CKD患者中的证据。

主要发现

  • CREDENCE试验表明卡格列净可预防肾衰竭和心血管事件。
  • SGLT2抑制剂的获益是在当前标准治疗基础上额外获得的。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The advent of sodium-glucose cotransporter 2 (SGLT2) inhibitors represents a major advance for people with type 2 diabetes (T2DM) and chronic kidney disease (CKD). The results of the Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) trial have clearly demonstrated that canagliflozin prevents kidney failure and cardiovascular events. The results from three other large-scale randomized trials, collectively enrolling >30 000 participants, have provided further evidence that the effects of SGLT2 inhibition on major kidney outcomes in people with T2DM may be present across the class, although this will only be known for certain when Dapagliflozin and Renal Outcomes and Cardiovascular Mortality in Patients with CKD (DAPA-CKD) (NCT03036150) and The Study of Heart and Kidney Protection with Empagliflozin (EMPA-KIDNEY) (NCT03594110) are reported over coming years. Importantly, the benefits of SGLT2 inhibition have been achieved in addition to the current standard of care. This review summarizes evidence for SGLT2 inhibition in people with T2DM and CKD, evaluates key patient characteristics and concomitant drug use that may influence the use of these drugs in people with CKD, discusses current guideline recommendations and explores how these drugs may be used in people with CKD in the future, including in combination with other treatments.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Neuen BL, Jardine MJ, Perkovic V, et al. Sodium-glucose cotransporter 2 inhibition: which patient with chronic kidney disease should be treated in the future? Nephrol Dial Transplant. 2020. PMID: 32003833. doi:10.1093/ndt/gfz252

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。